A Phase 2 Biomarker Study of Parathyroid Tumor Clonal Status in Primary Hyperparathyroidism
Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY
To define the frequency of monoclonal-X and polyclonal-X tumors in PHPT participants having parathyroidectomy (PTX) and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will compare surgical and pathologic outcomes to tumor clonal status in a multicenter cohort of patients having bilateral neck exploration (BNE) and PTX (primary objectives).
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:
• Diagnosed with nonfamilial primary hyperparathyroidism biochemically confirmed by measurement of serum calcium and intact PTH within 60 days of enrollment.
• Female.
• Age ≥ 18 years
• Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).
Locations
United States
Alabama
University of Alabama-Birmingham
RECRUITING
Birmingham
California
University of California-Department of Surgery
RECRUITING
San Francisco
Pennsylvania
Hospital of the University of Pennsylvania
RECRUITING
Philadelphia
Contact Information
Primary
John A Olson, MD
jaolsol@wustl.edu
(314) 362-8020
Backup
Kathleen Harris
harrisk@wustl.edu
(314) 273-1433
Time Frame
Start Date: 2023-04-11
Estimated Completion Date: 2027-01
Participants
Target number of participants: 839
Related Therapeutic Areas
Sponsors
Leads: Washington University School of Medicine